公开(公告)号：US20240041851A1

公开(公告)日：2024-02-08

申请号：US18265030

申请日：2021-12-03

申请人： THE GENERAL HOSPITAL CORPORATION ,  THE BRIGHAM AND WOMEN'S HOSPITAL, INC.

发明人： Vamsi Mootha ,  Benjamin Gewurz

IPC分类号： A61K31/4412 ,  A61K31/4162 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/426 ,  A61K31/427 ,  A61K31/198 ,  A61K31/4418 ,  A61K31/505 ,  A61K45/06 ,  A61P31/14

CPC分类号： A61K31/4412 ,  A61K31/4162 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/426 ,  A61K31/427 ,  A61K31/198 ,  A61K31/4418 ,  A61K31/505 ,  A61K45/06 ,  A61P31/14

摘要： A method of treating and preventing viral infection in a subject comprising administering an effective amount of one or more inhibitors of folate or one-carbon metabolism pathways to the subject.

公开(公告)号：US20240033253A1

公开(公告)日：2024-02-01

申请号：US17876811

申请日：2022-07-29

申请人： Chinese PLA General Hospital

发明人： Cuiping Zhang ,  Yaxi Wang ,  Kui Ma ,  Xiaobing Fu

IPC分类号： A61K31/427 ,  A61K9/06 ,  A61K9/127 ,  A61P17/02

CPC分类号： A61K31/427 ,  A61K9/06 ,  A61K9/127 ,  A61P17/02

摘要： The present disclosure provides a photocurable hydrogel loaded with VH298-modified exosome and a method of preparation and use thereof, belonging to the technical field of medical materials. In the present disclosure, an engineered exosome (VH-EVs) is prepared by combining an exosome with VH298, a hypoxia-inducible factor 1 alpha (HIF-1α) stabilizer; and a solid auxiliary material is loaded by a GelMAhydrogel. The material is not only conducive to sustained release of the engineered exosome, but improves angiogenesis and accelerate wound healing, showing a relatively high value for use.

公开(公告)号：US20240009220A1

公开(公告)日：2024-01-11

申请号：US18205745

申请日：2023-06-05

申请人： Gilead Sciences, Inc.

发明人： Roy Maxim Bannister ,  John P. Bilello ,  Jared D. Pitts

IPC分类号： A61K31/706 ,  A61K31/427 ,  A61K31/4025 ,  A61P31/14

CPC分类号： A61K31/706 ,  A61K31/427 ,  A61K31/4025 ,  A61P31/14

摘要： The present disclosure relates to methods for treating viral infections in a patient that is not pregnant. Also provided are combination treatments for viral infections in a human in need thereof.

公开(公告)号：US20230349923A1

公开(公告)日：2023-11-02

申请号：US18212542

申请日：2023-06-21

申请人： Maximus Diagnostic Technologies, LLC

发明人： Julia J. Liu

IPC分类号： G01N33/68 ,  C07K16/24 ,  C07K16/28 ,  A61P1/00 ,  A61K31/4035 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/496 ,  A61K31/519

CPC分类号： G01N33/6893 ,  C07K16/241 ,  C07K16/2839 ,  A61P1/00 ,  A61K31/4035 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/496 ,  A61K31/519 ,  G01N2800/065 ,  G01N2800/52 ,  C07K2317/24 ,  A61K2039/55

摘要： In some embodiments, the invention provides a method for identifying an agent beneficial to treat a patient with inflammatory bowel disease comprising: a) determining a status of an intestinal barrier in the patient; and b) categorizing the status as severe dysfunction or moderate dysfunction, wherein a patient categorized as having severe dysfunction is identified as a patient who will benefit from treatment with an agent selected from the group consisting of an anti-TNF agent and/or an anti-IL-12/23 agent, and a patient categorized as having moderate dysfunction is identified as a patient who will benefit from treatment with an anti-integrin agent, an anti-janus kinase agent, and/or and a sphingosine-1-phosphate receptor agonist agent.

公开(公告)号：US20230339871A1

公开(公告)日：2023-10-26

申请号：US18022117

申请日：2021-08-18

申请人： METREA BIOSCIENCES, INC.

发明人： Paul Da Silva Jardine ,  Frederick Dewey ,  Joshua Hoffman

IPC分类号： C07D277/04 ,  C07D417/06 ,  A61K31/4439 ,  A61K31/426 ,  C07D333/22 ,  A61K31/381 ,  C07D413/06 ,  A61K31/4178 ,  C07D215/48 ,  C07D401/12 ,  A61K31/4709 ,  A61K31/4704 ,  C07D263/06 ,  C07D217/26 ,  A61K31/47 ,  A61P1/16 ,  A61K31/4166 ,  A61K31/427 ,  A61K45/06

CPC分类号： C07D277/04 ,  C07D417/06 ,  A61K31/4439 ,  A61K31/426 ,  C07D333/22 ,  A61K31/381 ,  C07D413/06 ,  A61K31/4178 ,  C07D215/48 ,  C07D401/12 ,  A61K31/4709 ,  A61K31/4704 ,  C07D263/06 ,  C07D217/26 ,  A61K31/47 ,  A61P1/16 ,  A61K31/4166 ,  A61K31/427 ,  A61K45/06

摘要： The present disclosure is generally directed to modulators of hydroxysteroid dehydrogenase enzymes useful in the treatment of diseases and disorders modulated by said enzyme and having the Formula (I), Formula (II), or Formula (III).

公开(公告)号：US11787794B2

公开(公告)日：2023-10-17

申请号：US16676630

申请日：2019-11-07

申请人： Temple University—Of The Commonwealth System of Higher Education

发明人： Jean-Pierre J. Issa ,  Hanghang Zhang ,  Magid Abou-Gharbia ,  Wayne E. Childers ,  George C. Morton

IPC分类号： A61K31/427 ,  C07D417/14 ,  A61K45/06 ,  A61K31/706 ,  A61P35/00 ,  C07D417/06

CPC分类号： C07D417/14 ,  A61K31/427 ,  A61K31/706 ,  A61K45/06 ,  A61P35/00 ,  C07D417/06 ,  A61K2300/00 ,  A61K31/427 ,  A61K2300/00 ,  A61K31/706 ,  A61K2300/00

摘要： The present invention includes novel aminothiazole compounds of formula (I), which are useful in preventing or treating cancer in a subject in need thereof. The present invention also includes methods of preventing or treating cancer in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of formula (I)

公开(公告)号：US11779561B2

公开(公告)日：2023-10-10

申请号：US17590771

申请日：2022-02-01

申请人： SyneuRx International (Taiwan) Corp.

发明人： Guochuan Emil Tsai ,  Yi-Wen Mao ,  Lu-Ping Lu ,  Wei-Hua Chang ,  Han-Yi Hsieh ,  Jhe Wei Hu ,  Tsai-Miao Shih ,  ChanHui Huang

IPC分类号： A61K31/351 ,  A61K31/235 ,  A61K9/00 ,  A61K31/513 ,  A61K31/427 ,  A61K31/4709 ,  A61K31/472 ,  A61K31/4433 ,  A61K31/685 ,  A61K38/21 ,  A61K31/46 ,  A61K38/16 ,  A61K39/395 ,  A61K31/675 ,  A61K31/395 ,  A61K31/353 ,  A61K31/499 ,  A61K31/16 ,  A61K31/426 ,  A61K31/4045 ,  A61K31/343 ,  A61K31/13 ,  A61K31/4245 ,  A61K31/7072 ,  A61K31/708 ,  A61K31/506 ,  A61K31/52 ,  A61K31/551 ,  A61K31/4985 ,  A61K31/553 ,  A23L33/00 ,  A23L33/10 ,  A61P31/14 ,  A61K31/7032 ,  A61K45/06

CPC分类号： A61K31/351 ,  A23L33/10 ,  A23L33/40 ,  A61K9/008 ,  A61K9/0056 ,  A61K9/0078 ,  A61K31/13 ,  A61K31/16 ,  A61K31/235 ,  A61K31/343 ,  A61K31/353 ,  A61K31/395 ,  A61K31/4045 ,  A61K31/426 ,  A61K31/427 ,  A61K31/4245 ,  A61K31/4433 ,  A61K31/46 ,  A61K31/472 ,  A61K31/4709 ,  A61K31/499 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/513 ,  A61K31/52 ,  A61K31/551 ,  A61K31/553 ,  A61K31/675 ,  A61K31/685 ,  A61K31/708 ,  A61K31/7032 ,  A61K31/7072 ,  A61K38/16 ,  A61K38/21 ,  A61K38/212 ,  A61K38/217 ,  A61K39/3955 ,  A61K45/06 ,  A61P31/14 ,  A23V2002/00

摘要： A method of treating coronavirus infection, comprising administering to a subject in need thereof an effective amount of a composition, wherein the composition comprises one or more compounds of Formula (I):




or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230293498A1

公开(公告)日：2023-09-21

申请号：US18018997

申请日：2021-07-30

申请人： Emory University ,  Children's Healthcare of Atlanta, Inc.

发明人： Eric Sorscher ,  Haian Fu ,  Huw Davies ,  Jeong Hong ,  Yuhong Du ,  Andras Rab ,  Candela Manfredi ,  Xun Yang ,  Zhi Ren

IPC分类号： A61K31/427 ,  A61K31/433 ,  A61K31/4155

CPC分类号： A61K31/427 ,  A61K31/433 ,  A61K31/4155

摘要： This disclosure relates to compounds that are cystic fibrosis transmembrane conductance regulator (CFTR) modulators and pharmaceutical compositions containing the same. In certain embodiments, this disclosure relates to methods of managing a CFTR related disease or condition or respiratory distress comprising administering an effective amount of a CFTR modulator disclosed herein to a subject in need thereof.

公开(公告)号：US11760754B2

公开(公告)日：2023-09-19

申请号：US16761210

申请日：2018-11-02

申请人： UNIVERSITÉ DE MONTRÉAL

发明人： Yves Gareau ,  Stéphane Gingras ,  Yves Chantigny ,  Gaoqiang Yang ,  Guy Sauvageau ,  Irène Baccelli ,  Anne Marinier

IPC分类号： C07D413/12 ,  C07D263/32 ,  C07D263/34 ,  C07D417/12 ,  A61K31/421 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/501 ,  A61K31/506 ,  A61P35/02 ,  C07D249/04 ,  C07D277/24 ,  G01N33/50

CPC分类号： C07D417/12 ,  C07D249/04 ,  C07D263/32 ,  C07D263/34 ,  C07D277/24 ,  C07D413/12 ,  G01N33/5011

摘要： Heterocyclic compounds of Formula (I) and pharmaceutically acceptable salt thereof are disclosed. The use of such heterocyclic compounds and pharmaceutically acceptable salt thereof for the treatment of cancers, and more particularly cancers sensitive to mitochondrial activity inhibition and increased reactive oxygen species (ROS) levels, is also disclosed. Such cancers include acute myeloid leukemia (AML), preferably AML characterized by certain features, such as high level of expression of one or more Homeobox (HOX)-network genes, high and/or low expression of specific genes, the presence of one or more cytogenetic or molecular risk factors such as intermediate cytogenetic risk, Normal Karyotype (A/K), mutated NPM1, mutated CEBPA, mutated FLT3, mutated DNMT3A, mutated TET2, mutated IDH1, mutated IDH2, mutated RUNX1, mutated WT1, mutated SRSF2, intermediate cytogenetic risk with abnormal karyotype (intern(abnK)), trisomy 8 (+8) and/or abnormal chromosome (5/7), and/or a high leukemic stem cell (LSC) frequency.

公开(公告)号：US11724989B2

公开(公告)日：2023-08-15

申请号：US17481660

申请日：2021-09-22

申请人： Vettore, LLC

发明人： Kenneth Mark Parnell ,  John McCall

IPC分类号： C07D231/12 ,  A61P35/00 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/5377 ,  A61K45/06 ,  C07D401/06 ,  C07D405/12 ,  C07D409/04 ,  C07D417/04

CPC分类号： C07D231/12 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/5377 ,  A61K45/06 ,  A61P35/00 ,  C07D401/06 ,  C07D405/12 ,  C07D409/04 ,  C07D417/04 ,  A61K31/415 ,  A61K2300/00 ,  A61K31/4155 ,  A61K2300/00 ,  A61K31/5377 ,  A61K2300/00 ,  A61K31/427 ,  A61K2300/00 ,  A61K31/4439 ,  A61K2300/00

摘要： Provided herein is a method for treating a monocarboxylate transporter MCT4-mediated disorder in a subject in need thereof. The method comprises the step of administering to the subject a compound of structural Formula I




and/or a salt thereof. The treatment of the monocarboxylate transporter MCT4-mediated disorder may inhibit activity of MCT4, or a mutant thereof, sometimes with at least a 100-fold selectivity for MCT4 over MCT1.